Merck Falls Into Q3 Results as Analysts Push Targets Higher

MRK closed Monday at $140.61, down 3.2% on the day and 2.1% on the week, a notably weak session given that its closest pharmaceutical peers gained between 1.2% and 4.9% over the same period. JNJ added 4.9% on the week, BMY rose 4.7%, and LLY climbed 3.1%. The gap between Merck and the peer group widened further into Tuesday's Q3 results, with the stock now down 5.5% over the past month.

The analyst community has been moving the other way. Barclays raised its price target to $180 on Monday, the same day the stock fell 3.2%, maintaining an Overweight rating. JPMorgan lifted its target to $165 in early October, also at Overweight, while Morgan Stanley trimmed marginally to $177 but kept its Overweight. Several neutral-rated firms also raised targets in recent weeks: Citigroup moved to $145 and Cantor Fitzgerald to the same level, both from lower starting points. The consensus mean target now stands at $159.76, implying roughly 14% upside from Monday's close. That is a wider implied return than was on offer a week ago, driven entirely by the stock's slide rather than a downward revision to targets.

The disagreement is concentrated on what happens to Merck after Keytruda loses exclusivity in 2028 to 2029. The constructive case rests on recent Phase 3 successes across sacTMT, INT, tulisokibart, and islatravir/lenacapavir, which the company argues materially de-risk the revenue bridge beyond the patent cliff. Winrevair and Capvaxive add near-term commercial breadth. The cautious case points to Keytruda approaching peak penetration in its core tumour types, rising mandatory German rebates and price-volume agreements compressing international pricing, accelerating erosion in Januvia and Janumet from IRA pricing and generics, and a $400 million IPR&D charge that has already hit the P&L. EV/EBITDA has compressed to 12.9 over the past month, and the trailing PE of 17.5 reflects those concerns.

Nothing in the positioning data suggests short sellers are pressing an aggressive bet. Short interest at 1.17% of free float is minimal and has drifted slightly lower over the past week. Borrow is effectively free at 0.21% annualised, and availability is maximal. The put/call ratio of 0.77 is fractionally below its 20-day average of 0.79, a fraction of a standard deviation below normal, pointing to options markets that are, if anything, slightly less defensive than usual. The stock's decline is not being driven by short pressure.

The Q3 print will test whether the revenue and margin trajectory from Keytruda's current-cycle performance, alongside the newer commercial launches, is tracking closely enough to the pipeline narrative to justify the gap between a $140 stock and a Street consensus pointing to $160.